Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Scilex Holding Company Announces Collaboration with ACEA Therapeutics for ZTlido® Expansion in Far East Region
Jul 17, 2024
Contract Type
partnership
DallasBiotechnologyHealth CareMedicalTherapeutics
Description
Scilex Holding Company has entered into a Memorandum of Understanding (MOU) for collaboration agreement with ACEA, a China-based company, to support the expansion of ZTlido® program in ex-US and potentially provide additional access to patients in certain key markets in the Far East region, including mainland China, Taiwan, Hong Kong, and Macau. This collaboration opens opportunities for Scilex to expand its non-opioid pain management portfolio in the Greater China region.
Company Information
Company
Nanoscope Therapeutics
Location
1312 BROWN TRAIL
Dallas, Texas, United States
About
Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in H1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial, also in the first half of 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.
DallasBiotechnologyHealth CareMedicalTherapeutics